A Pilot Study Using Autologous Regulatory T Cell Infusion Zortress (Everolimus) in Renal Transplant Recipients

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

March 15, 2019

Primary Completion Date

April 10, 2024

Study Completion Date

April 10, 2024

Conditions
End Stage Renal DiseaseKidney Transplant
Interventions
DRUG

Treg

Collect white blood cells to isolate Treg cells for expansion. Once the blood cells are collected the cells will be cultured in the laboratory and will be expanded. After approximately 3 weeks in culture, the cells will have increased in number and be ready for the autologous Treg cell infusion.

Trial Locations (1)

40536

University of Kentucky Medical Center, Lexington

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

Roberto Gedaly

OTHER